Novartis (NVS) Issues Positive Update from Cosentyx CLEAR Study in Psoriasis

Novartis (NVS) Issues Positive Update from Cosentyx CLEAR Study in Psoriasis

Cosentyx is the first fully human interleukin-17A inhibitor approved for adults to treat moderate-to-severe plaque psoriasis, and was recently approved for the treatment of psoriatic arthritis and ankylosing spondylitis in the EU and US. "Cosentyx

(Visited 1 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.